Trinity Biotech (TRIB) Liabilities and Shareholders Equity (2016 - 2025)
Trinity Biotech's Liabilities and Shareholders Equity history spans 17 years, with the latest figure at $105.2 million for Q4 2025.
- On a quarterly basis, Liabilities and Shareholders Equity rose 1.82% to $105.2 million in Q4 2025 year-over-year; TTM through Dec 2025 was $405.5 million, a 5.22% increase, with the full-year FY2025 number at $105.2 million, up 1.82% from a year prior.
- Liabilities and Shareholders Equity hit $105.2 million in Q4 2025 for Trinity Biotech, up from $99.6 million in the prior quarter.
- Over the last five years, Liabilities and Shareholders Equity for TRIB hit a ceiling of $136.0 million in Q1 2021 and a floor of $59.4 million in Q4 2023.
- Historically, Liabilities and Shareholders Equity has averaged $99.0 million across 5 years, with a median of $98.8 million in 2022.
- Biggest five-year swings in Liabilities and Shareholders Equity: crashed 35.47% in 2023 and later surged 73.79% in 2024.
- Tracing TRIB's Liabilities and Shareholders Equity over 5 years: stood at $118.9 million in 2021, then dropped by 22.53% to $92.1 million in 2022, then plummeted by 35.47% to $59.4 million in 2023, then surged by 73.79% to $103.3 million in 2024, then grew by 1.82% to $105.2 million in 2025.
- Business Quant data shows Liabilities and Shareholders Equity for TRIB at $105.2 million in Q4 2025, $99.6 million in Q2 2025, and $103.3 million in Q4 2024.